PBT2 News, page-21

I have read once again the last ann made by ATH about PBT2. Recent news revealed many important info in this ann.

https://cdn-api.markitdigital.com/apiman-gateway/CommSec/commsec-node-api/1.0/event/document/1410-02325202-2O4ECFDAJH6B6J5P3N23587ATS/pdf?access_token=0007c2gVQIMo1jhcVdvPFiYdib6I

ATH must have knew the data from the recent UQ research paper before the ann. Kempler even talked about Covid-19. The recent published paper mentioning Covid-19 was just submitted in Nov. 2021.

“The critical and urgent importance of this work is amplified in the current context of Covid-19, because secondary bacterial infections associated with viral pandemics are an important cause of mortality3 The need for effective antimicrobial regimens is very high,” added Mr Kempler.

From the following statements, I do believe ATH and the Unis have been planning for new human Clinical Trial for PBT2.

Under the licence, Alterity has secured the worldwide exclusive right to patented technology to develop and commercialise therapies that re-sensitise bacteria to antibiotics. The licensed technology combines Alterity’s PBT2 and other zinc ionophores with commonly used antibiotics to treat infections caused by multidrug resistant bacteria. This is an opportunity for Alterity to further leverage its investment in PBT2.
(Telling people ATH will lead the commercialization)

In exchange for the grant of exclusive worldwide rights, once Alterity generates commercialization revenue, UniQuest is entitled to receive certain payments including milestone and royalty payments commensurate with academic licenses.
(Telling what are the Unis' rewards from the deal with ATH)

Alterity intends to direct new resources to the project with no impact on its lead commercialisation program for ATH434, which is advancing to Phase 2 in Multiple System Atrophy, a Parkinsonian disorder with no approved therapy.
(New money may be generated to support the commercialization including conducting new clinical trials for PBT2. Clinical Trials for ATH434 and PBT2 will be in parallel.)

IMO, ATH has already made the deal with the unis. Once they found the money, new clinical trial on Human might happen.